T cells generally recognize peptide antigens bound to MHC proteins through contacts with residues found within or immediately flanking the seven-to nine-residue sequence accommodated in the MHC peptide-binding groove. However, some T cells require peptide residues outside this region for activation, the structural basis for which is unknown. Here, we have investigated a HIV Gagspecific T cell clone that requires an unusually long peptide antigen for activation. The crystal structure of a minimally antigenic 16-mer bound to HLA-DR1 shows that the peptide C-terminal region bends sharply into a hairpin turn as it exits the binding site, orienting peptide residues outside the MHC-binding region in position to interact with a T cell receptor. Peptide truncation and substitution studies show that both the hairpin turn and the extreme C-terminal residues are required for T cell activation. These results demonstrate a previously unrecognized mode of MHC-peptide-T cell receptor interaction.
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antigen presentation ͉ receptors ͉ antigen ͉ protein conformation C lass II MHC proteins are cell-surface glycoproteins that bind antigens in the form of short peptides and present them for recognition to T cell receptors (TCRs) on the cell surface of CD4 ϩ T cells (1) . Naturally processed peptides isolated from class II MHC proteins found in antigen-presenting cells are usually 15-25 residues long (2, 3) . The central region of these peptides interacts directly with class II MHC proteins, typically with specific recognition of an approximate nine-residue stretch (4) . X-ray crystallography of human and murine class II MHC proteins has revealed that peptides bind to the protein in an extended polyproline type II conformation, with several peptide side chains bound into polymorphic pockets that line the peptide-binding groove (5) (6) (7) (8) (9) (10) (11) (12) . A hydrogen-bond network between the conserved residues on the class II MHC and the peptide main-chain carbonyl and amide groups, independent of the sequence of the peptide, stabilizes the MHC-peptide complex (13) , and enforces the polyproline conformation that directs some of the side chains into the MHC pockets and leaves the others accessible for TCR interactions (14) . Generally, pockets accommodate the side chains of peptide residues at the P1, P4, P6, and P9 positions, with smaller pockets or shelves in the binding site accommodating the P3 and P7 residues. Minor variations on this theme have been observed, for example, in some complexes the P9 interactions are weak or absent (5, 10) . In the canonical conformation, the side chains of residues at positions P Ϫ1, P2, P5, and P8 are solvent-accessible and point toward the TCR, with portions of other side chains and the peptide main chain also exposed for potential TCR interaction in the central region of the complex.
The interaction of TCR with MHC-peptide complexes also is expected to be relatively stereotyped, with complementaritydetermining regions (CDRs) from the V␣ and V␤ domain lying across the peptide-MHC complex, typically with CDR3 loops of both variable domains extending down over the center of the peptide and the CDR1 and CDR2 loops contacting the ␣-helices (4, 15). Detailed structural information on the MHC-TCR interaction is available only for two class II MHC-TCR complexes (16) (17) (18) , in which TCR CDR3 loops contact the MHC-bound peptides within the region circumscribed by MHC-peptide contacts, at the P Ϫ1, P2, P3, P5, and P8 positions. For both these systems, earlier mapping experiments had identified these positions as sites where amino acid substitution abrogated T cell activation without disturbing MHCpeptide interaction (16, 17) . Mutagenesis studies have suggested that many other MHC-TCR pairs interact in this manner (ref. 4 and references therein). The structures provide no evidence for TCR contacts with peptide residues outside the peptide-binding groove, although peptide-mapping experiments have suggested that for some peptides the flanking P11 residue also can be an important T cell contact (18) (19) (20) (21) .
Here, we investigate a complex that uses a different mode of class II MHC peptide-TCR interaction. The crystal structure of an HIV Gag(p24)-derived peptide bound to HLA-DR1 reveals an unusual bent conformation for the bound peptide. A hairpin turn involving residues P9-P12 folds the peptide back over itself after it exits the binding groove, orienting the P13 side chain for interaction with TCR. A Gag(p24)-restricted CD4 ϩ T cell clone requires both the hairpin turn and the P13 residue for activation.
Methods
Peptide Synthesis. Peptides were synthesized by using solid-phase fluorenylmethoxycarbonyl chemistry, and were cleaved, deprotected, and purified by using standard methods (22) . The identity and homogeneity of each peptide was verified by using reversephase HLPC and matrix-assisted laser desorption ionization͞time-of-flight MS. Peptide concentration was determined by using amino acid analysis.
Protein Expression and Purification. For peptide binding experiments, the extracellular portion of HLA-DR1 (DRA*0101, DRB1*0101) was produced in insect cells as soluble empty ␣␤ heterodimers, as described (23) . For x-ray crystallography, the extracellular portion of HLA-DR1 was produced by expression of isolated subunits in Escherichia coli inclusion bodies, followed by refolding in vitro and immunoaffinity purification as described (24) . SEC-3B2 superantigen was expressed as a soluble protein in E. coli and isolated from the periplasmic fraction as described (25) .
T Cell Activation Assay. The CD4 ϩ T cell clone AC-25 and the corresponding autologous B cell line were derived as described (26) .
Briefly, the clone was derived after stimulating peripheral blood mononuclear cells with whole p24 antigen, resting for 2 weeks, then restimulating and plating at limiting dilution on a round-bottom 96-well plate. The AC- 25 H-thymidine was added, and, after an additional 17 h, plates were harvested onto glass fiber filters. Results were expressed as the difference between the counts in the presence and absence of antigen, with differences Ͼ1,000 considered to be significant (26) . For IFN-␥ enzyme-linked immunospot assays, B lymphoblastoid cell lines (5 ϫ 10 4 ), peptide antigen (1 g͞ml), and AC-25 T cells (50 cells per well) were added to 96-well plates coated with anti-IFN-␥ antibody (Mabtech, Mariemont, OH). After overnight incubation, cells were discarded and the plates were washed, and captured IFN-␥ was detected by using biotinylated anti-IFN-␥ (Endogen, Cambridge, MA), streptavidin-alkaline phosphatase (Mabtech), and nitroblue tetrazolium͞ 5-bromo-4-chloro-3-indolyl phosphate (Bio-Rad) was added. Background responses to wells with no antigen or irrelevant antigen ranged from 0 to 2.5 spots per well. Responses greater than five spots per well and more than five times the maximum background were considered significant.
Peptide-Binding Assay. A competition assay was used to determine binding affinities of peptides. HLA-DR1 (25 nM) was mixed together with biotinylated Ha[306-318] peptide (25 nM) and various concentrations of unlabeled competitor peptide (10 Ϫ12 to 10 Ϫ5 M). The mixtures were incubated for 3 days at 37°C in 100 mM sodium phosphate buffer, pH 5.5, containing 50 mM NaCl, 1 mg͞ml PMSF, 37 g͞ml iodoacetamide, 10 mM EDTA, 0.02% NaN 3 , and 0.5 mg͞ml octyl glucoside, followed by detection of bound biotinylated peptide using an immunoassay that used anti-DR1 capture antibody LB3.1 and alkaline phosphate-labeled streptavidin.
Crystallization. HLA-DR1-peptide complexes, purified by gel filtration, were mixed with equimolar SEC3-3B2, and crystals were grown at 4°C by vapor diffusion in hanging drops, by using 1 l of protein complex (10 mg͞ml) mixed with 1 l of precipitant solution (5-10% ethylene glycol͞100 mM sodium acetate, pH 5.2-5.6͞ 2-6% polyethylene glycol 4000 for Gag[PG13] or 2-6% polyethylene glycol͞5000 monomethyl ether for Gag[PP16]). For x-ray diffraction experiments, the crystals were soaked for Ϸ1 min in a cryoprotectant solution consisting of 25% ethylene glycol in the mother liquor and were then flashed-cooled in liquid nitrogen.
Data Collection and Processing. For the Gag[PG13] complex, a 2.25-Å data set was collected from a single crystal (300 ϫ 200 ϫ 200 m) on an R-AXIS IV image plate detector by using CuK␣ radiation from a rotating anode source. For the Gag[PP16] complex, a 2.45-Å data set was collected on a single crystal (80 ϫ 60 ϫ 60 m) on a Mar180 image plate detector, also by using CuK␣ radiation. Collected data were processed and scaled by using the programs DENZO, SCALEPACK, and the CCP4 package (27, 28 (29) and manual inspection and rebuilding were carried out by using the program XTALVIEW (30) . The final model was verified for distortions on the secondary structure features by using the program PROCHECK (31) . Coordinates and structure factors for HLA-DR1͞Gag[PP16]͞SEC3-3B2 and HLADR1͞Gag[PG13]͞SEC3-3B2 have been deposited in the PDB database (ID codes 1SJE and 1SJH, respectively).
Results

Residues at the C Terminus of an HIV-Gag-Derived Peptide Are
Required for T Cell Activation but Not for MHC-Peptide Interaction. A CD4 ϩ T cell clone (AC-25) isolated from an individual acutely infected with HIV-1 recognizes an antigen derived from the HIV Gag (p24) protein bound to the human class II MHC protein HLA-DR1. As reported (32), AC-25 requires an unusually long peptide for activation. Only three residues can be removed from either end of a Gag(p24)-derived 22-mer without affecting T cell activation (Fig. 1A and ref. 32) . Removal of additional residues from either the N or C terminus of the minimal gag-derived 16-mer PEVIPMFSALSEGATP (Gag[PP16]) results in abrogation of T cell activation, as shown by a cellular proliferation assay (Fig. 1 A) , and also in abrogation of cytotoxicity and cytokine secretion functions (32) .
For HLA-DR1, the most important determinants of peptide binding are a hydrophobic residue at position P1 and a small residue at position P6, with additional but weaker preferences at P4, P7, and P9 (33, 34) . Within the Gag[PP16] peptide, the preferred binding frame is expected to be VIPMFSALS (key MHC-peptide contacts are underlined) (35, 36) . A shorter Gag-derived peptide containing this sequence, PEVIPMFSALSEG (Gag[PG13]), binds to HLA-DR1 with an apparent dissociation constant of Ͻ10 nM, which is essentially identical to that of the longer Gag[PP16] peptide (Fig.  1B ) However, this peptide is inactive (Fig. 1A, open squares) . The inability of the Gag[PG13] peptide to induce activation responses in a T cell clone that recognizes the longer peptide is unexpected, and could indicate an unusual binding frame or mode of T cell interaction. Table 1 ). The complexes were crystallized in the presence of SEC3-3B2, an affinity-matured variant of a staphylococcal enterotoxin that interacts with HLA-DR1 outside the binding groove, and which has been used to promote crystallization (37) . For both complexes, electron density for HLA-DR1, peptide, and superantigen was clear and continuous except for HLA-DR1 ␤l09-111, a disordered loop away from the peptide-binding site, for SEC3-3B2 residues 99-105, a region located away from the interaction site with HLA-DR1, and for the Gag[PP16] terminal proline residue, which was not observed. Electron density for the Gag[PP16] penultimate threonine was observed but was not sufficiently clear to allow definitive placement of the side chain.
Both Gag[PP16] and Gag[PG13] peptides bind in the expected frame, with Val (P1), Met (P4), Ser (P6), and Ser (P9) accommodated in pockets in the peptide-binding groove (Fig. 2 A and B , and Fig. 6 , which is published as supporting information on the PNAS web site). The Gag[PG13] peptide adopts the usual polyproline conformation. The Gag[PP16] peptide adopts that same conformation within the MHC peptide-binding groove, but, just outside the groove, the peptide bends sharply at P10 and doubles back over itself (Fig. 2C ). These differences are highlighted in the Gag[PP16] Ϫ Gag[PG13] difference Fourier map (Fig. 2 D and E) . The largest features in this map are a positive peak above the peptide P9-P11 residues (8.4) together with a negative peak beyond the Gag[PG13] C terminus (7.5), which indicate the deviation of the Gag[PP16] peptide from the usual extended conformation, and positive and negative peaks (Ϯ 6.5) surrounding the side chain of Leu (P8), which indicate an Ϸ90°rotation of the side chain (Fig. 2  D and E) . peptide P13 (Thr) side chain near the P8 (Leu) side chain, and changes the orientation of Leu (P8) relative to that found in the Gag[PG13] peptide (Fig. 2C ).
The C-Terminal Region of Gag[PP16] Adopts a Type II ␤-Turn. Both Gag[PG13] and Gag[PP16]
peptides bind with the usual main-chain hydrogen-bonding scheme involving HLA-DR1 residues Gln␣9, Asn␣62, Asn␣69, Arg␣76, Asp␤57, Trp␤61, Arg␤71, His␤81, and Asn␤82 (although with intervening waters for the Gag[PP16] interaction with Arg␣76 and Asp␤57; Fig. 3A ). The Gag[PP16] peptide makes an additional intramolecular main-chain hydrogen bond, involving the carbonyl oxygen of the P9 residue (Ser) and the amide nitrogen of P12 (Ala; Fig. 3B ). This interaction is characteristic of a ␤-turn, a four-residue structural motif found frequently in proteins (38) . In Gag[PP16], the SEGA (P9-P12) sequence forms a ␤-turn, with main-chain backbone and angles characteristic of the type II ␤-turn (Fig. 3B) . In type II ␤-turns, the oxygen atom of the carbonyl of residue 2 (P10) crowds the C ␤ atom of residue 3, which is therefore usually glycine (39) . The Gag [PP16] peptide has glycine at this position (P11).
This bent conformation has not been observed previously among complexes of peptides bound to class II MHC molecules. An alignment of Gag[PP16] with all other crystal structures of HLA-DR1 complexes exhibiting ordered density beyond P10 is shown in Fig. 3C . In each of these structures, the peptide extends straight out of the binding site, without any pronounced bends or turns.
The C-Terminal Hairpin Is Required for T Cell Activation. Alaninescanning mutagenesis of the Gag[PP16] peptide was used to determine the importance of the C-terminal hairpin in AC-25 TCR interaction, and to confirm the physiological relevance of the peptide conformation observed in the crystal structure. Each Gag[PP16] peptide residue except for Ala (P7) and Ala (P12) was changed independently to alanine, and standard MHC peptide binding and T cell proliferation assays were performed (Fig. 4 A and B) .
In the MHC peptide-binding assay (Fig. 4 B and C) , no singlealanine substitution abolished MHC-peptide interaction, but significant reductions in binding affinity were observed upon alanine substitution of Val (P1) and Met (P4), and, to a lesser extent, Ser (P9). These effects are consistent with the binding frame observed in the crystal structures. [Both Ala and Ser are preferred residues at P6 (34), and no significant effect is expected or observed for this substitution]. In the T cell activation assay, alanine substitutions of Glu (P Ϫ1), Ile (P2), Phe (P5), and Thr (P13) had dramatic effects, abolishing activation at all concentrations tested (Fig. 4 A and C) . In the Gag[PP16] crystal structure, the side chains of residues at the P Ϫ1, P2, and P5 positions were observed to be oriented away from the peptide-binding site as in other class II MHC-peptide complexes, and the effects of alanine substitutions at these positions are consistent with conventional MHC-TCR interaction. In the Gag[PP16] crystal structure, the hairpin turn orients Thr (P13) above the bulk of the peptide, in the vicinity of the P8 side chain. The large effect of Thr (P13)-to-alanine substitution at this position on T cell activation but not MHC-peptide interactions suggests that this residue and the hairpin turn play an important role in TCR interaction.
To further establish the contribution of the residues at the Gag[PP16] C terminus to T cell activation, additional substitutions were analyzed at Gly(P11) and Ala(P12) (Fig. 4D) . Ala(P12) was substituted by glycine, to evaluate a possible role of the alanine side chain in TCR recognition, which would not have been apparent in the initial alanine scan. This substitution was tolerated well by the TCR (Fig. 4D, f) . To evaluate the role of the reverse turn, Gly(P11) was substituted by proline, which (unlike alanine) cannot be accommodated in a type II turn. Gly(P11)-to-Pro substitution abrogated T cell activation (Fig. 4D, Ⅺ) , again highlighting the importance of the hairpin turn in T cell activation. 
Discussion
The crystal structure of the HIV Gag-derived peptide Gag [PP16] bound to HLA-DR1 shows that it binds in an unexpected bent conformation, with a hairpin turn at one end of the binding groove that orients its C-terminal region above the remainder of the peptide and in position to interact with TCR. Truncation analysis shows that this C-terminal region is important for recognition by a CD4 ϩ T cell clone derived from an HIV-infected person. The effects of alanine scanning and site-specific substitutions introduced into the peptide show that the Thr residue at position P13 has no effect on binding to the class II MHC protein, but is crucial for TCR interaction, along with conventional T cell contacts at P Ϫ1, P2, and P5 (Fig. 5) . The hairpin turn would appear to be important in aligning the threonine for recognition by TCR because introduction of a proline residue that interferes with turn formation blocked T cell activation.
The Gag[PP16] C-terminal hairpin would appear to represent a physiologically relevant conformation, rather than one induced only by crystallization or recombinant MHC peptide production. First, several ␤-turn prediction algorithms (39) (40) (41) (42) identify the SEGA (P9-P12) sequence as having strong type II ␤-turn potential, with contributions from the Glu at position 2, in addition to the strongly preferred Gly at position 3. The Thr (P13) side chain is in van der Waals contact with Leu (P8), which also would tend to stabilize the turn and would be able to form an intrachain hydrogen bond between the Thr hydroxyl and the main-chain carbonyl oxygen at position 1 of the type II ␤-turn. Moreover, no crystal contacts are found in the vicinity of the hairpin. Second, AC-25 T cell recognition of the Gag[PP16] peptide appears to depend on the Cterminal ␤-hairpin turn, as shown by the Gly(P11)-to-Pro substitution, which abrogates T cell activation, as well as by the pattern of important T cell contact residues (Fig. 5) . The AC-25 T cell clone specific for this conformation was isolated from an HIV-infected subject who was treated with antiretroviral therapy during primary HIV infection. The clonotype presumably was elicited in response to viral infection, and was selected in vitro by using peripheral blood mononuclear cells stimulated with intact Gag protein. This finding suggests that both naturally infected and Gag protein-treated cells present on their surface an activating Gag-derived epitope that presumably includes the hairpin conformation. However, we note that the hairpin is not obligatory for T cell recognition of this region of Gag: the same Gag (24) epitope as studied here has been identified also as the target of an HLA-DR4-restricted T cell clone (32) and another HLA-DR1-restricted T cell clone (43) . Both of these clones appear to recognize a conventional 10-residue sequence, EVIPMFSALS, contained within the Gag[PG13] sequence. Finally, whereas P13 is well outside the range of peptide residues generally considered to be seen by the TCR, comparison of the Gag[PP16] structure with previously determined class II MHC-TCR complexes (44) (45) (46) suggests that a TCR in a normal orientation could contact Thr directly by interacting with the CDR3 and͞or CDR2 loops on V␤.
How frequently might we expect such unconventional recognition of bent peptides? Except for the HLA-DR1-Gag[PP16] complex reported here, hairpin turns or other bent or bulged conformations have not been observed in the class II MHC crystal structures reported to date. However, several of the complexes crystallized do not contain residues outside of the P1-P10 region, and many complexes carry their peptides as covalent attachments to the MHC ␤-subunit, where the linker between the peptide C terminus and the MHC ␤ N terminus could interfere with potential turn formation (5, 7, (47) (48) (49) (50) . Thus, at present we may not have a complete picture of the degree of potential conformational variability for peptides bound to class II MHC proteins. The large number of main-chain hydrogen bonds in the central region of the peptide constrain the conformation of a peptide bound to class II MHC proteins, but, outside of the P1-P10 region, the peptide would appear to be unconstrained by the MHC. A peptide turn or bend would therefore have to be stabilized by interactions provided by the peptide, as observed here for Gag[PP16]. In general, the conformational stability of structures formed by short peptides is thought to be low, but any particular sequence able to form a stable conformation potentially could be recognized by TCR.
TCR recognition of residues outside the MHC peptide-binding groove has been observed previously in cellular studies. A flanking tryptophan at the P11 position of a lysozyme peptide bound to IA k has been shown to be important in T cell activation (18) (19) (20) . Such flanking interactions have been proposed to be a common feature of MHC-TCR interaction (20) , although this is controversial (51) . Note that the P11 side chain is oriented toward the TCR for a MHC-bound peptide canonical polyproline repeat, and does not require a peptide bend, bulge, or turn for recognition by TCR. There have been fewer reports of T cells that are sensitive to peptide residues lying further outside a reliably predicted MHC-binding region, or with patterns of T cell contact residues that suggest deviations from the canonical polyproline extended structure. In one study, Met was found at P12 (48, 52) , and is located at the end of a sequence with high propensity for ␤-turn formation (41) . In another, critical T cell contacts were mapped to positions several residues N-terminal to the expected MHC-binding regions (19) .
In conclusion, these studies show that peptides can bind to class II MHC proteins in a previously unobserved conformation in which residues outside the binding groove can bend back over the peptide and become accessible for T cell recognition. These results provide evidence for a mode of MHC peptide-TCR interaction that should be considered more widely in prediction, testing, and design of putative T cell antigens.
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